Cargando…

Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis

Detalles Bibliográficos
Autores principales:	Baghizadeh, Somayyeh, Sahraian, Mohammad Ali, Ghahari, Mojgan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2016
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852071/ https://www.ncbi.nlm.nih.gov/pubmed/27141277

Ejemplares similares

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Clinical and demographic factors affecting disease severity in patients with multiple sclerosis
por: Baghizadeh, Somayeh, et al.
Publicado: (2013)

The prevalence of multiple sclerosis in Tehran, Iran, in 2020
por: Eskandarieh, Sharareh, et al.
Publicado: (2023)

Is it time to revise the classification of geographical distribution of multiple sclerosis?
por: Sahraian, Mohammad Ali, et al.
Publicado: (2012)

Is pulmonary arterial hypertension associated with interferon-β therapy for multiple sclerosis reversible? A case study to explore the complexity
por: Anthi, Anastasia, et al.
Publicado: (2020)

Significant Increase in the Prevalence of Multiple Sclerosis in Iran in 2011
por: Izadi, Sadegh, et al.
Publicado: (2014)

New diagnostic criteria for multiple sclerosis in patients with clinically isolated syndromes: Some questions could be raised during clinical practice
por: Sahraian, Mohammad Ali, et al.
Publicado: (2012)

Reply to Urbanization Theory for Growing Trend of Multiple Sclerosis Letter
por: DEHGHANI, Rouhullah, et al.
Publicado: (2017)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports
por: Rastkar, Mohsen, et al.
Publicado: (2023)

The first presentation of COVID-19 two hours after vaccination in a patient with multiple sclerosis: Can COVID vaccine provoke cytokine storm in a patient with asymptomatic COVID-19?
por: Ghadiri, Fereshteh, et al.
Publicado: (2021)

Increasing Incidence and Male to Female Sex Ratio of Multiple Sclerosis in Tehran, Iran: A Population-Based Study
por: Kamali, Hoda, et al.
Publicado: (2022)

The first attack of multiple sclerosis presented immediately after voluntary and intensive weight loss: A case series
por: Bitarafan, Sama, et al.
Publicado: (2017)

Sporadic Porphyria Cutanea Tarda in a Patient with Multiple Sclerosis Treated with Interferon Beta 1-a Therapy: A Case Report
por: Carrieri, Pietro, et al.
Publicado: (2013)

Ameliorated nailfold capillary morphology of patients with pulmonary arterial hypertension in systemic sclerosis, treated with riociguat
por: Sugimoto, Tomohiro, et al.
Publicado: (2023)

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2018)

Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-β-1b: a case report
por: Sahraian, Mohammad Ali, et al.
Publicado: (2013)

Beta-thalassemia intermedia with ischemic transients misdiagnosed as multiple sclerosis: A case report
por: Ghadiri, Fereshteh, et al.
Publicado: (2021)

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Overdue to understand anticoagulation in pulmonary arterial hypertension
por: Parikh, Kishan S., et al.
Publicado: (2018)

Pulmonary arterial hypertension incidence in Latvia in 2019
por: Kaulins, Ricards, et al.
Publicado: (2022)

Pulmonary arterial hypertension due to antiphospholipid syndrome initially mimicking chronic thromboembolic pulmonary hypertension
por: Yeo, Jina, et al.
Publicado: (2022)

Pulmonary artery sarcoma presenting as chronic thromboembolic pulmonary hypertension (CTEPH)
por: Ampatzidou, Fotini, et al.
Publicado: (2023)

Considering Personalized Interferon Beta Therapy for COVID-19
por: Dorgham, Karim, et al.
Publicado: (2021)

Dasatinib-induced reversible pulmonary arterial hypertension in a pediatric patient with BCR/ABL1+ lymphoblastic lymphoma from chronic myeloid leukemia
por: Han, Hye-ji, et al.
Publicado: (2022)

The relation between genital wart and multiple sclerosis
por: Aghaei, Maryam, et al.
Publicado: (2017)

Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2018)

Reversible therapy-related dysplastic hematopoiesis following Beta Interferon Therapy in Multiple Sclerosis Patients: Report of 2 Cases
por: Nabavi, Seyed Massood, et al.
Publicado: (2011)

Reply to “Bone morphogenetic protein's contribution to pulmonary artery hypertension”
por: King, Tyler, et al.
Publicado: (2016)

Risk assessment in pulmonary arterial hypertension patients with multiple comorbidities and/or advanced age—Where do we stand and what's next?
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients
por: Maghbooli, Zhila, et al.
Publicado: (2023)

Management of hospitalized patients with pulmonary arterial hypertension and COVID-19 infection
por: Sahay, Sandeep, et al.
Publicado: (2020)

Preoperative pulmonary artery hypertension as a risk factor: the tip of the iceberg
por: Engin, Mesut, et al.
Publicado: (2023)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Knowledge and attitude assessment of Iranian multiple sclerosis patients receiving interferon beta
por: Abolfazli, Roya, et al.
Publicado: (2014)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mb359s892kqltn2adpdekjsdor